Still at risk of big capitulation, with little hope of experiencing even one last spike, your best move remains the same: steer clear of GME stock.
Here are five short squeeze stocks many investors are putting on their radar right now as a result of higher short interest and borrow fees.
The FDA approval is a near term catalyst that will take NVAX stock to new highs over the coming months. Buy NVAX stock in the dip.
GOEV stock isn't going to amount to much at this rate. Investors should understand that its peers are pulling in front as you read this.
DIDI stock faces immense regulatory woes which will continue to impact the company's performance for the foreseeable future. DiDi Global is a name to avoid.
SOS stock offers the ability to invest in cryptos without doing so directly but such an argument is not exclusive to the company.
Buying SOFI stock below $20 is a great bet as it has the potential and ability to soar higher in the coming months.
While Bitcoin has attracted most of the headlines, the risk-reward profile now favors speculative digital assets like Floki Inu.
U.S. legalization, and Tilray's global expansion efforts could enable TLRY stock to climb significantly above its current levels.
Shiba Inu proponents are not trying to change the world but instead just have a love for dogs. This type of honesty is refreshing for SHIB-USD.
While it’s easy to get caught up in the current narrative for Cardano, the past reveals much more useful information. Keep an eye on ADA-USD trading volume.
ADA-USD is betting on the DeFi future and it could be the edge Cardano needs to outdo its rivals in the long run.
Bitcoin is the digital version of gold. And if Bitcoin gets as big as gold, you’re talking an $11 trillion market on 21 million tokens.
WISH stock's monthly active users have dropped by a massive margin and are a major long-term concern for the firm.
Going short on Camber Energy is a situation where the potential profits aren't enough to counter the danger of a short squeeze. Going long is a wager on renewed market madness. A tough situation to assess, it's best to invest elsewhere. Skip on CEI stock.
The five analysts covering Aterian give ATER stock a median target price of $14. I’m not sure what they see in the consumer products company.
Coupang can transport its successful, proven methods to Japan and Taiwan, stoking a CPNG stock rally over the next 12 months.
With a new oral antiviral drug by Merck potentially over the horizon, NVAX stock may be trading on borrowed time.
Globalstar lacks fundamental reasons that could move GSAT stock higher, while the downside risk is more likely.
Polestar CEO says the electric vehicle startup is not a "Tesla killer," but GGPI stock could still provide multi-bagger returns.